Companies in #Retinal Disease

Aldeyra Therapeutics is a clinical-stage biotechnology company developing therapies that modulate reactive aldehyde species (RASP), a class of molecules the company links to inflammation across ocular, systemic and metabolic conditions. Its lead candidate, reproxalap, is a topical RASP modulator for the signs and symptoms of dry eye disease and allergic conjunctivitis that has received three Complete Response Letters from the FDA; the company has announced an intent to file a formal dispute resolution request over the most recent letter. The pipeline also includes ADX-2191, a preservative-free intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa, and orally administered next-generation RASP modulators such as ADX-629 and ADX-248.

IRIDEX Corporation is an ophthalmic medical-device company that develops, manufactures and markets laser-based systems, delivery devices and consumable procedure probes for the treatment of glaucoma and retinal diseases. Founded in 1989 and long headquartered in Mountain View, California, the company's intellectual property centers on its proprietary MicroPulse technology, a tissue-sparing, sub-threshold laser approach that delivers laser energy in short pulses with cooling intervals, alongside the Cyclo G6 glaucoma laser platform, the MicroPulse P3 delivery device and the G-Probe family of transscleral probes. The company completed the relocation of its manufacturing operations from Mountain View to San Jose, California in October 2026 as part of a cost-reduction programme.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.